China’s BCI Industry Hits Tipping Point as Investment Surges Past $9.6 Billion
China’s brain-computer interface (BCI) industry has reached an inflection point in 2026, with investment in the sector exceeding 70 billion yuan (approximately $9.6 billion) in the first half of the year alone — more than double the total for all of 2025. The surge comes as the country’s first invasive BCI medical device received regulatory approval, clinical trials accelerated across multiple companies, and a decade-long policy framework reached its culmination.
According to data from IT Juzi cited by Xinhua News, BCI investment grew from 10.6 billion yuan in 2024 to 27.23 billion yuan in 2025, before exploding to over 70 billion yuan across more than 60 deals in just the first six months of 2026. The trajectory signals a market that has moved beyond early-stage curiosity into full-blown investor conviction.
A Decade of Policy Preparation
China’s BCI acceleration is no accident — it is the product of a carefully orchestrated policy chain stretching back a decade. The foundation was laid in 2016 when “Brain Science and Brain-like Research” was included in the 13th Five-Year Plan. From there, the government methodically built out each layer: scientific research funding through the China Brain Project, application guidance directing BCI toward clinical rehabilitation in 2023, ethics guidelines and industry standards in 2024, and a comprehensive seven-department industrial policy in July 2025.
The policy chain reached its most significant milestone in March 2026, when BCI was included in the State Council Government Work Report for the first time, listed alongside quantum technology, embodied AI, and 6G as a priority “future industry.” As detailed in a comprehensive policy inventory by AI Scientist, this represented the final step in translating strategic vision into administrative action.
First Device Approval and Clinical Progress
The most tangible breakthrough came when China’s National Medical Products Administration (NMPA) approved the world’s first invasive BCI medical device — Broca’s “Implantable BCI Hand Motor Function Compensation System” (NEO) — for clinical use. This marked a watershed moment, transforming BCI from a research concept into a reimbursable medical treatment.
Multiple companies are racing toward commercialization. Xinzhida’s “Beinao No.1” semi-invasive BCI system has enrolled over 50% of its clinical trial patients. Jieti Medical, which raised 500 million yuan in a round led by Alibaba in March 2026, is preparing a 256-channel wireless system for large-scale multi-center trials. Gestalt Technology’s ultrasound BCI super factory in Chengdu began operations on June 26, with Phase I covering 2,000 square meters.
The Investment Boom: Betting on the Future
The scale of capital flowing into BCI has drawn attention — and caution — from industry observers. Yao Dezhong, Director of the Sichuan Brain Science Institute, described the phenomenon to Xinhua as “a typical case of ‘investing in the future,’” noting that the 70 billion yuan in half-year financing “exceeds the substantive commercialization progress of the vast majority of current enterprises.”
Gong Yi, founder of Dongwei Semiconductor, offered a vivid illustration of the sector’s growth: “Last year I had about a dozen invasive BCI companies in my field of vision. This year, I hear there are already over 200.” The observation, reported by PEdaily, underscores both the excitement and the potential for a valuation bubble.
Payment Pathways: Solving the “Who Pays?” Question
A critical enabler of China’s BCI push has been the early establishment of pricing and insurance mechanisms. Hubei Province issued China’s first BCI medical service pricing standards, and Shanghai included Broca’s product in medical insurance reimbursement. Li Yuan, Board Secretary of Xinzhida, told Xinhua that “medical insurance reimbursement not only reduces patient burden but also signifies the state’s recognition of the clinical value of BCI technology. It is a key lever for promoting large-scale commercialization.”
On June 30, 2026, the NMPA issued classification and naming guidelines for BCI medical devices, clarifying that invasive and implantable products are Class III medical devices — the highest regulatory tier. This provides the regulatory certainty that companies need to plan long-term investments.
China vs. the US: Different Paths to the Same Destination
While Elon Musk’s Neuralink pursues high-bandwidth brain control and vision restoration with approximately 21 clinical patients, China has taken a more pragmatic approach focused on medical rehabilitation. Guo Liang, Founder of Brain Era, acknowledged the gap in research history — “China’s invasive BCI scientific research spans less than a decade, while the US has 40-50 years of history” — but pointed to China’s structural advantages in clinical resources and supply chain.
According to CCID Consulting, China’s BCI market is projected to reach 61.4 billion yuan by 2028, with a compound annual growth rate of 17.7% from 2024 to 2028. The government has set a target of cultivating 2-3 globally competitive BCI enterprises by 2030.
What to Watch Next
As China’s BCI industry moves from investment frenzy to commercial reality, several developments bear watching. BrainCo’s confidential IPO filing with the Hong Kong Stock Exchange in January 2026 could open the door for a wave of BCI company listings. The entry of tech giants Alibaba and Tencent into the sector signals that BCI is being viewed as a next-generation human-computer interaction platform. And the competition among Chinese cities — from Beijing to Chengdu to Nanjing — to become BCI hubs will likely intensify.
The risks are real: a potential valuation bubble, clinical bottlenecks as resources struggle to keep pace with investment, and unresolved ethical questions around brain data privacy. But after a decade of systematic preparation, China’s BCI industry has crossed the threshold from laboratory curiosity to industrial reality. The question is no longer whether BCI will arrive, but how quickly it will scale.